Patient perspectives on depot buprenorphine treatment for opioid addiction – a qualitative interview study

Original research
par
Johnson, Björn, Olivia Liahaugen Flensburg & Andrea Johansson Capusan

Date de publication

2022

Géographie

Sweden

Langue de la ressource

English

Texte disponible en version intégrale

Oui

Open Access / OK to Reproduce

Oui

Évalué par des pairs

Yes

L’objectif

The purpose of this study was to explore patients’ experiences of depot injections and their reasons for continuing, discontinuing, or declining depot injection treatment.

Constatations/points à retenir

Buprenorphine depot injections may have social, practical, and psychological benefits compared to other formulations. However, depot injections are not perceived as an attractive option by all patients. Trust, consistent and adequate information, and awareness of the implications of the pharmaceutical atmosphere should be considered when introducing new medications.

La conception ou méthodologie de recherche

Semi-structured qualitative interviews with 32 people, 14 of whom had ongoing depot injection treatment, 11 who had discontinued depot-injections and switched to other medication and seven who had declined treatment with depot formulations.

Mots clés

Substitution/OAT
About PWUD
Barriers and enablers